Trump’s FTC Continues The Mission Of Eliminating Orange Book’s Improper Patent Listings
The Third Warning Letter Campaign Addressed 17 Branded Products
In a somewhat surprising move, president Donald Trump’s Federal Trade Commission carries the torch in a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon told Generics Bulletin what it means for the generic drug industry.
